Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679263 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
A Phase 2 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00679263 is a Phase 2 study that has completed, run by MediciNova. The registered enrollment target is 17 participants.
The verdict
NCT00679263, a Phase 2 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
Interventions
- DRUG Placebo
- DRUG MN-221
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679263
The ClinicalTrials.gov registry entry for NCT00679263 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00679263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00679263 about?
NCT00679263 is a clinical study titled "Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma". The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
What is the current status of trial NCT00679263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2008-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00679263?
The interventions under investigation include: Placebo (DRUG), MN-221 (DRUG).
Who is sponsoring clinical trial NCT00679263?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.